Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93848ArticlesСтатьиResearch ArticleEffektivnost' sovremennykh podkhodov v terapii endometritaЭффективность современных подходов в терапии эндометритаShurshalinaA. VШуршалинаА. ВУниверситет Тафтса, США15062013156VOL 15, NO6 (2013)ТОМ 15, №6 (2013)404228122021Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93848

Воспалительные заболевания органов малого таза (ВЗОМТ) продолжают составлять в структуре гинекологической патологии не менее 50–60%, несмотря на блестящие успехи фармакотерапии и многократные пересмотры клинических рекомендаций по диагностике и терапии. В литературе активно обсуждается целесообразность снижения диагностического порога для ВЗОМТ, учитывая огромную долю субклинических форм, сложности диагностики и потенциальный риск для репродуктивного здоровья. За последнее десятилетие это привело к неоднократному пересмотру минимальных критериев диагностики, необходимых для выявления ВЗОМТ в различных медицинских сообществах – американском, европейском, австралийском [5, 10, 22]. Несвоевременная диагностика ВЗОМТ приводит к развитию ряда осложнений и отсроченных последствий: трубно-перитонеальная форма бесплодия, внематочная беременность, синдром хронической тазовой боли, диспареуния, синдром Фитц-Хью-Кертиса [27–29]. В последние годы появились данные о повышении риска рака яичников, инфаркта миокарда и инсульта, ассоциированных с воспалительными процессами в малом тазу

Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011; с. 704–24.Bebear C, Barbeyrac B, Pereyre S. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.Boothby M, Page J, Pryor R, Ross J.D. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first - line treatment of uncomplicated non - gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.Carvalho F.M, Aguiar F.N, Tomioka R. Functional endometrial polyps in infertile asymptomatic patients: a possible evolution of vascular changes secondary to endometritis. Eur J Obstet Gynecol Reprod Biol 2013.CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR12.Check J.H, Choe J.K, Amui J. Evaluation of the importance of late follicular phase endometrial echo patterns and pregnancy outcome following embryo transfer by evaluating infertile donor/recipient pairs. Clin Exp Obstet Gynecol 2011; 38 (4): 318–9.Check J.H. Comparison of pregnancy rate following in vitro fertilization - embryo transfer between the donors and the recipients in a donor oocyte program. J Assist Reprod Genet 1992; 9 (3): 248–50.Chen P.C, Tseng T.C, Hsieh J.Y, Lin H.W. Association between stroke and patients with pelvic inflammatory disease: a nationwide population - based study in Taiwan. Stroke Jul 2011; 42 (7): 2074–6.Cicinelli E, De Ziegler D, Nicoletti R. Poor reliability of vaginal and endocervical cultures for evaluating microbiology of endometrial cavity in women with chronic endometritis. Gynecol Obstet Invest 2009; 68 (2): 108–15.European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.orgHaggerty C.L, Ness R.B. Newrest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44 (7): 953–60.Heystek M, Ross J.D. PID Study Group. A randomized double - blind comparison of moxifloxacin and doxycycline/metronidazole/ ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.Kasius J.C, Fatemi H.M, Bourgain C. The impact of chronic endometritis on reproductive outcomes. Fertil Steril 2011; 96 (6): 1451–6.Lauper U. Adnexitis and pelvic inflammatory disease. Gynakol Geburtshilfliche Rundsch 2005; 45 (1): 14–8.Lin H.W, Tu Y.Y, Lin S.Y et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population - based study. Lancet Oncol 2011; 12 (9): 900–4.Liou T.H, Wu C.W, Hao W.R et al. Risk of myocardial infarction in women with pelvic inflammatory disease. Int J Cardiol 2012; 20.Miron N.D et al. Bacretiological agents which play a role in the development of infertility. Acta Microbiol Immunol Hung 2013; 60 (1): 41–53.Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue - cultured epithelial cells. Antimicrob Agents Chemother 1999; 43 (1): 12–5.RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease 2003, 2009. http://www.rcog.org.ukRoss J.D, Cronjé H.S, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi - centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.Solomkin J, Zhao Y.P, Ma E.L. Moxifloxacin is non - inferior to combination therapy with ceftriaxone plus metronidazole in patients with community - origin complicated intra -abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynecol Obstet 2008; 102 (2): 132–6.Stein G.E, Schooley S, Tyrrell K.L. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra - abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.Sweet R.L. Pelvic inflammatory disease: current concepts of diagnosis and management. C Infect Dis Rep 2012.Taylor B, Ness R, Darville T. Microbial correlates of delayed care for pelvic inflammatory disease. Sex Transm Dis 2011; 38 (5): 434–8.Trent M, Bass D, Ness R.B. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Trans Dis 2011; 8 (9): 879–81.Wiesenfeld H.C, Hillier S.L, Meyn L.A. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012; 120 (1): 37–43.World Health Organization. Sexually transmitted infections. http://www.who.int/mediacentre/factsheets/fs110/en